Summary Twenty patients receiving a variety of emetogenic cytotoxics (including cisplatin in 5) were given a single i.v. infusion of 40,ugkg-1 of BRL43694 (as the hydrochloride salt) in successive groups of 3-4 patients between 0-6 hours after chemotherapy. Eleven patients were completely protected from vomiting; 9 had mild to moderate nausea and vomiting, but none severe enough to require alternative anti-emetic 'rescue'. In 4 of the patients in whom BRL43694 was delayed until 4-6h after chemotherapy, vomiting had already begun; in each case There is increasing evidence that the anti-emetic effect of high dose metoclopramide is mediated by 5-hydroxytryptamine antagonism at the 5HT-3 receptor (Costall et al., 1986 . Fozard & Mobarok, 1978 . Miner & Sanger, 1986 . The recent synthesis of specific 5HT-3 receptor antagonists (Richardson et al., 1985) has led to the demonstration in animal models (Miner & Sanger, 1986 ) and in man (Cunningham et al., 1987; Leibungut & Lancranjan, 1987) of the importance of 5HT-3 receptor antagonism in anti-emesis.
Nausea and vomiting remain major problems in cancer chemotherapy despite recent advances, such as the use of high dose metoclopramide. One major disadvantage of high dose metoclopramide is the relatively high incidence of extrapyramidal side effects in young patients. Even with optimum use of established agents control of emesis is poor in a proportion of patients, especially following administration of cisplatin chemotherapy.
There is increasing evidence that the anti-emetic effect of high dose metoclopramide is mediated by 5- hydroxytryptamine antagonism at the 5HT-3 receptor (Costall et al., 1986 . Fozard & Mobarok, 1978 . Miner & Sanger, 1986) . The recent synthesis of specific 5HT-3 receptor antagonists (Richardson et al., 1985) has led to the demonstration in animal models (Miner & Sanger, 1986 ) and in man (Cunningham et al., 1987; Leibungut & Lancranjan, 1987) of the importance of 5HT-3 receptor antagonism in anti-emesis.
BRL43694 [Endo-N-(9-methyl-9-azabicyclo-(3,3, I)-non-3-yl)-I -methyl-indazole-3-carboxamide] has been recently developed by Beecham Pharmaceuticals Research Division as a selective 5HT-3 antagonist. In common with other agents of this class it rapidly abolishes vomiting induced by cisplatin in ferrets (Boyle et al., 1987 
Results

Efficacy of BRL43694
The results of this part of the study are shown in Table II . Overall 7 patients experienced neither nausea nor vomiting. In 4 patients despite a lack of nausea noted on VAS, mild nausea was reported to the observer. In the remaining 9 patients mild to moderate nausea occurred. Nine patients vomited or had episodes of dry retching (mean number of episodes = 2.3; maximum = 4). This was usually observed more than 8-12h following the single infusion of BRL43694. No patient required alternative anti-emetic 'rescue'.
Fourteen patients expressed a preference for BRL43694 over standard anti-emetics given with their second course of chemotherapy; one patient preferred standard anti-emetics, 4 had no preference and one patient was not evaluable because of a change in chemotherapy between courses one and two. There was no clear advantage of delaying administration of BRL43694 for 2, 4 or 6h rather than administration immediately following chemotherapy. ., 1988) .
The terminal phase half-lives ranged from 1.5 to 13.3h in 13 patients, but was much longer (28.7h) in patient 10 though there was no obvious clinical indication of possible problems in drug disposition in this patient. The mean terminal half-life is 9h in these 14 patients. This is longer than was seen in 10 healthy subjects receiving BRL43694 at 30-40 ygkg-1 (4.0h) although the range was also broad (2.5 to 7.1 h) in those individuals 
Discussion
This study shows BRL43694 to be an effective and very well tolerated anti-emetic at an intravenous dose of 40,ugkg-1. Our patients were receiving a variety of cytotoxics, some more emetogenic than others, and it is worth noting that only one of the five patients receiving cisplatin was completely protected by the single dose of BRL43694, although all had some amelioration of nausea and vomiting (in comparison to course two). However, from consideration of the animal toxicology and volunteer studies, it is evident that there is scope for dose escalation and scheduling changes of BRL43694 which may result in even better control of cisplatin induced emesis.
Such nausea and vomiting as were observed tended to start more than 8-12 hours post BRL43694 (see Table II ). This might suggest that there is some threshold plasma level below which anti-emetic efficacy is compromised. This would suggest that multiple dosing may be appropriate. We could not find a definite relationship between the time of antiemetic administration with respect to chemotherapy, and the subsequent anti-emetic efficacy of BRL43694. It is probable that any such relationship would require a larger patient group to become evident.
There was no clear correlation between anti-emetic efficacy and either peak plasma concentration of BRL43694 or the area under the plasma concentration time curves for individual patients in this study.
BRL43694 was well tolerated at this dosage, in particular we did not observe any dysphoria, extra-pyramidal effects or the degree of sedation noted with anti-emetics such as metoclopramide or the cannabinoids. This is encouraging in that it suggests there is a possibility of co-administration of BRL43694 with established anti-emetics in the future, if the 5HT-3 receptor blockers are found not to be totally protective in their own right.
A remarkable finding in this study was the ability of BRL43694 to immediately terminate established vomiting in the 4 patients treated in this way. This effect mimics that seen in pre-clinical studies of cisplatin induced vomiting in ferrets (Boyle et al., 1987) . Previous attempts to treat patients in this way have involved aggressive multi-drug regimens and have met with variable success; together with increased risk of adverse effects or drug interaction with the cytotoxics used (Piezia et al., 1984) .
The observed differences in BRL43694 disposition between patients and volunteers are interesting, though such differences are common in patients with malignancies. Nonetheless, the maximum concentrations achieved in both groups are comparable.
These results are similar to those published for other 5HT-3 antagonists (Cunningham et al., 1987; Leibungut & Lancranjan, 1987) and confirm the anti-emetic potential for this class of drugs. Currently further studies are underway to define optimum dosage schedules, and it is hoped that a repeated dose (6-hourly) regime based on the pharmacokinetic profile of BRL43694 may enhance the effect, particularly against the most emetogenic cytotoxic agents.
